298 related articles for article (PubMed ID: 18723473)
1. Silencing of Abcd1 and Abcd2 genes sensitizes astrocytes for inflammation: implication for X-adrenoleukodystrophy.
Singh J; Khan M; Singh I
J Lipid Res; 2009 Jan; 50(1):135-47. PubMed ID: 18723473
[TBL] [Abstract][Full Text] [Related]
2. Caffeic acid phenethyl ester induces adrenoleukodystrophy (Abcd2) gene in human X-ALD fibroblasts and inhibits the proinflammatory response in Abcd1/2 silenced mouse primary astrocytes.
Singh J; Khan M; Singh I
Biochim Biophys Acta; 2013 Apr; 1831(4):747-58. PubMed ID: 23318275
[TBL] [Abstract][Full Text] [Related]
3. HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes.
Singh J; Khan M; Singh I
J Lipid Res; 2011 Nov; 52(11):2056-69. PubMed ID: 21891797
[TBL] [Abstract][Full Text] [Related]
4. Abcd2 is a strong modifier of the metabolic impairments in peritoneal macrophages of ABCD1-deficient mice.
Muneer Z; Wiesinger C; Voigtländer T; Werner HB; Berger J; Forss-Petter S
PLoS One; 2014; 9(9):e108655. PubMed ID: 25255441
[TBL] [Abstract][Full Text] [Related]
5. Very long-chain fatty acid accumulation causes lipotoxic response via 5-lipoxygenase in cerebral adrenoleukodystrophy.
Khan M; Singh J; Gilg AG; Uto T; Singh I
J Lipid Res; 2010 Jul; 51(7):1685-95. PubMed ID: 20173212
[TBL] [Abstract][Full Text] [Related]
6. ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy.
Baarine M; Beeson C; Singh A; Singh I
J Neurochem; 2015 May; 133(3):380-96. PubMed ID: 25393703
[TBL] [Abstract][Full Text] [Related]
7. Cholesterol regulates ABCD2 expression: implications for the therapy of X-linked adrenoleukodystrophy.
Weinhofer I; Forss-Petter S; Zigman M; Berger J
Hum Mol Genet; 2002 Oct; 11(22):2701-8. PubMed ID: 12374760
[TBL] [Abstract][Full Text] [Related]
8. Astrocytes and mitochondria from adrenoleukodystrophy protein (ABCD1)-deficient mice reveal that the adrenoleukodystrophy-associated very long-chain fatty acids target several cellular energy-dependent functions.
Kruska N; Schönfeld P; Pujol A; Reiser G
Biochim Biophys Acta; 2015 May; 1852(5):925-36. PubMed ID: 25583114
[TBL] [Abstract][Full Text] [Related]
9. Metformin-induced mitochondrial function and ABCD2 up-regulation in X-linked adrenoleukodystrophy involves AMP-activated protein kinase.
Singh J; Olle B; Suhail H; Felicella MM; Giri S
J Neurochem; 2016 Jul; 138(1):86-100. PubMed ID: 26849413
[TBL] [Abstract][Full Text] [Related]
10. Substrate specificity overlap and interaction between adrenoleukodystrophy protein (ALDP/ABCD1) and adrenoleukodystrophy-related protein (ALDRP/ABCD2).
Genin EC; Geillon F; Gondcaille C; Athias A; Gambert P; Trompier D; Savary S
J Biol Chem; 2011 Mar; 286(10):8075-8084. PubMed ID: 21209459
[TBL] [Abstract][Full Text] [Related]
11. X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism is severely impaired in monocytes but not in lymphocytes.
Weber FD; Wiesinger C; Forss-Petter S; Regelsberger G; Einwich A; Weber WH; Köhler W; Stockinger H; Berger J
Hum Mol Genet; 2014 May; 23(10):2542-50. PubMed ID: 24363066
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of pharmacological induction of fatty acid beta-oxidation in X-linked adrenoleukodystrophy.
McGuinness MC; Zhang HP; Smith KD
Mol Genet Metab; 2001; 74(1-2):256-63. PubMed ID: 11592822
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9-mediated knockout of Abcd1 and Abcd2 genes in BV-2 cells: novel microglial models for X-linked Adrenoleukodystrophy.
Raas Q; Gondcaille C; Hamon Y; Leoni V; Caccia C; Ménétrier F; Lizard G; Trompier D; Savary S
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 May; 1864(5):704-714. PubMed ID: 30769094
[TBL] [Abstract][Full Text] [Related]
14. Impaired very long-chain acyl-CoA β-oxidation in human X-linked adrenoleukodystrophy fibroblasts is a direct consequence of ABCD1 transporter dysfunction.
Wiesinger C; Kunze M; Regelsberger G; Forss-Petter S; Berger J
J Biol Chem; 2013 Jun; 288(26):19269-79. PubMed ID: 23671276
[TBL] [Abstract][Full Text] [Related]
15. ABCD2 is a direct target of β-catenin and TCF-4: implications for X-linked adrenoleukodystrophy therapy.
Park CY; Kim HS; Jang J; Lee H; Lee JS; Yoo JE; Lee DR; Kim DW
PLoS One; 2013; 8(2):e56242. PubMed ID: 23437103
[TBL] [Abstract][Full Text] [Related]
16. Evidence of oxidative stress in very long chain fatty acid--treated oligodendrocytes and potentialization of ROS production using RNA interference-directed knockdown of ABCD1 and ACOX1 peroxisomal proteins.
Baarine M; Andréoletti P; Athias A; Nury T; Zarrouk A; Ragot K; Vejux A; Riedinger JM; Kattan Z; Bessede G; Trompier D; Savary S; Cherkaoui-Malki M; Lizard G
Neuroscience; 2012 Jun; 213():1-18. PubMed ID: 22521832
[TBL] [Abstract][Full Text] [Related]
17. Abcd1 deficiency accelerates cuprizone-induced oligodendrocyte loss and axonopathy in a demyelinating mouse model of X-linked adrenoleukodystrophy.
Martinović K; Bauer J; Kunze M; Berger J; Forss-Petter S
Acta Neuropathol Commun; 2023 Jun; 11(1):98. PubMed ID: 37331971
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of retinoids for induction of the redundant gene ABCD2 as an alternative treatment option in X-linked adrenoleukodystrophy.
Weber FD; Weinhofer I; Einwich A; Forss-Petter S; Muneer Z; Maier H; Weber WH; Berger J
PLoS One; 2014; 9(7):e103742. PubMed ID: 25079382
[TBL] [Abstract][Full Text] [Related]
19. Contiguous deletion of the X-linked adrenoleukodystrophy gene (ABCD1) and DXS1357E: a novel neonatal phenotype similar to peroxisomal biogenesis disorders.
Corzo D; Gibson W; Johnson K; Mitchell G; LePage G; Cox GF; Casey R; Zeiss C; Tyson H; Cutting GR; Raymond GV; Smith KD; Watkins PA; Moser AB; Moser HW; Steinberg SJ
Am J Hum Genet; 2002 Jun; 70(6):1520-31. PubMed ID: 11992258
[TBL] [Abstract][Full Text] [Related]
20. Thyroid hormone induction of the adrenoleukodystrophy-related gene (ABCD2).
Fourcade S; Savary S; Gondcaille C; Berger J; Netik A; Cadepond F; El Etr M; Molzer B; Bugaut M
Mol Pharmacol; 2003 Jun; 63(6):1296-303. PubMed ID: 12761339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
